{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:26:02Z","timestamp":1791923162905,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drup.2026.101445","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:22:53Z","timestamp":1783628573000},"page":"101445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting LIG1 to overcome oxaliplatin resistance by inducing PANoptosis in colorectal cancer"],"prefix":"10.1016","volume":"88","author":[{"given":"Quan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HongJian","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinsong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjunzi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhao","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinglei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinbing","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2026.101445_bib1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10555-023-10158-3","article-title":"Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments","volume":"43","author":"Abedizadeh","year":"2024","journal-title":"Cancer Metastas-.-. Rev."},{"key":"10.1016\/j.drup.2026.101445_bib2","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"International study of oxaliplatin\/5-fluorouracil\/leucovorin in the adjuvant treatment of colon cancer, oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andre","year":"2004","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101445_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf1344","article-title":"Processing of DNA single-strand breaks with oxidatively damaged ends by LIG1","volume":"53","author":"Balu","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drup.2026.101445_bib4","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1038\/s41467-022-35475-z","article-title":"Mechanism of human Lig1 regulation by PCNA in Okazaki fragment sealing","volume":"13","author":"Blair","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101445_bib5","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.drup.2026.101445_bib6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41422-025-01107-6","article-title":"Pyroptosis: molecular mechanisms and roles in disease","volume":"35","author":"Broz","year":"2025","journal-title":"Cell. Res."},{"key":"10.1016\/j.drup.2026.101445_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.critrevonc.2019.01.023","article-title":"Early colorectal cancer: diagnosis, treatment and survivorship care","volume":"136","author":"Buccafusca","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.drup.2026.101445_bib8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1186\/s12876-025-04405-w","article-title":"Prognostic factors and survival outcomes in colorectal cancer: insights from a Ghanaian cohort","volume":"25","author":"Buckman","year":"2025","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.drup.2026.101445_bib9","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41586-024-07620-9","article-title":"NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance","volume":"631","author":"Chen","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101445_bib10","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/0008-5472.CAN-07-6636","article-title":"Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair","volume":"68","author":"Chen","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101445_bib11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nrclinonc.2015.129","article-title":"First-line chemotherapy for mCRC-a review and evidence-based algorithm","volume":"12","author":"Cremolini","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101445_bib12","article-title":"CRISPR\/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer","volume":"135","author":"Fracassi","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drup.2026.101445_bib13","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1186\/s40001-025-03647-4","article-title":"LIG1 overexpression enhances DNA repair and immune escape leading to poor prognosis in osteosarcoma","volume":"30","author":"Fu","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.drup.2026.101445_bib14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13046-024-03089-6","article-title":"Cell death shapes cancer immunity: spotlighting PANoptosis","volume":"43","author":"Gao","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101445_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114445","article-title":"Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment","volume":"188","author":"Gao","year":"2022","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.drup.2026.101445_bib16","doi-asserted-by":"crossref","first-page":"D1528","DOI":"10.1093\/nar\/gkaf1191","article-title":"NPCDR 2.0: the activity and structure landscape of natural product-based drug combination","volume":"54","author":"Gao","year":"2026","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drup.2026.101445_bib17","first-page":"71","article-title":"Mechanism of lactic acidemia-promoted pulmonary endothelial cells death in sepsis: role for CIRP-ZBP1-PANoptosis pathway","volume":"11","author":"Gong","year":"2024","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.drup.2026.101445_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-020-01297-0","article-title":"Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma","volume":"20","author":"Guo","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101445_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","article-title":"Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies","volume":"9","author":"He","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101445_bib20","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.molcel.2023.12.041","article-title":"PARP5A and RNF146 phase separation restrains RIPK1-dependent necroptosis","volume":"84","author":"Hou","year":"2024","journal-title":"Mol. Cell."},{"key":"10.1016\/j.drup.2026.101445_bib21","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1200\/JCO.23.01889","article-title":"and O.s. group, Neoadjuvant chemotherapy with oxaliplatin and fluoropyrimidine versus upfront surgery for locally advanced colon cancer: the randomized, phase III OPTICAL Trial","volume":"42","author":"Hu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101445_bib22","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drup.2026.101445_bib23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jare.2025.02.016","article-title":"Comprehensive multi-omics analyses expose a precision therapy strategy that targets replication stress in hepatocellular carcinoma using WEE1 inhibition","volume":"78","author":"Jia","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.drup.2026.101445_bib24","doi-asserted-by":"crossref","first-page":"D1335","DOI":"10.1093\/nar\/gkae993","article-title":"CTR-DB 2.0: an updated cancer clinical transcriptome resource, expanding primary drug resistance and newly adding acquired resistance datasets and enhancing the discovery and validation of predictive biomarkers","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drup.2026.101445_bib25","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","article-title":"Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07","volume":"25","author":"Kuebler","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101445_bib26","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","article-title":"Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with tp53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101445_bib27","doi-asserted-by":"crossref","first-page":"W242","DOI":"10.1093\/nar\/gkab418","article-title":"GEPIA2021: integrating multiple deconvolution-based analysis into GEPIA","volume":"49","author":"Li","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drup.2026.101445_bib28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-022-00902-6","article-title":"Downregulation of MEIS1 mediated by ELFN1-AS1\/EZH2\/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer","volume":"7","author":"Li","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101445_bib29","article-title":"Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency","volume":"9","author":"Li","year":"2022","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.drup.2026.101445_bib30","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1038\/s41467-025-59505-8","article-title":"MS CETSA deep functional proteomics uncovers DNA repair programs leading to gemcitabine resistance","volume":"16","author":"Liang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101445_bib31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41392-022-00889-0","article-title":"Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis","volume":"7","author":"Lin","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101445_bib32","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/s41423-025-01329-z","article-title":"PANoptosis in cancer: bridging molecular mechanisms to therapeutic innovations","volume":"22","author":"Lin","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.drup.2026.101445_bib33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41392-024-01958-2","article-title":"Pyroptosis in health and disease: mechanisms, regulation and clinical perspective","volume":"9","author":"Liu","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101445_bib34","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.apsb.2024.12.014","article-title":"Remodeling tumor immunosuppressive microenvironment through dual activation of immunogenic panoptosis and ferroptosis by H(2)S-amplified nanoformulation to enhance cancer immunotherapy","volume":"15","author":"Luo","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.drup.2026.101445_bib35","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ejso.2020.09.017","article-title":"Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin","volume":"47","author":"Nagourney","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.drup.2026.101445_bib36","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1006\/bbrc.2001.5092","article-title":"Cloning, characterization, and expression of human LIG1","volume":"284","author":"Nilsson","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drup.2026.101445_bib37","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7150\/thno.91814","article-title":"Current evidence and therapeutic implication of PANoptosis in cancer","volume":"14","author":"Ocansey","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.drup.2026.101445_bib38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pilie","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101445_bib39","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","article-title":"Drug-tolerant persister cells in cancer: the cutting edges and future directions","volume":"20","author":"Pu","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101445_bib40","first-page":"226","article-title":"Colorectal cancer","volume":"184","author":"Rehman","year":"2021","journal-title":"Cells Enter. a Diapause- DTP State Surviv. Chemother. Cell."},{"key":"10.1016\/j.drup.2026.101445_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194761","article-title":"EZH2 inhibition and cisplatin as a combination anticancer therapy: an overview of preclinical studies","volume":"14","author":"Samarzija","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drup.2026.101445_bib42","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/s41467-023-37542-5","article-title":"PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer","volume":"14","author":"Shi","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101445_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1419126","article-title":"LIG1 is a novel marker for bladder cancer prognosis: evidence based on experimental studies, machine learning and single-cell sequencing","volume":"15","author":"Song","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drup.2026.101445_bib44","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jconrel.2022.09.013","article-title":"Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer","volume":"350","author":"Song","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drup.2026.101445_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092679","article-title":"Adjuvant chemotherapy for stage iii colon cancer","volume":"12","author":"Taieb","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2026.101445_bib46","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41591-023-02497-z","article-title":"First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b\/2 trial","volume":"29","author":"Thibaudin","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101445_bib47","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1021\/cr040498d","article-title":"DNA ligases: structure, reaction mechanism, and function","volume":"106","author":"Tomkinson","year":"2006","journal-title":"Chem. Rev."},{"key":"10.1016\/j.drup.2026.101445_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf299","article-title":"Molecular basis for RNA discrimination by human DNA ligase 1","volume":"53","author":"Tumbale","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.drup.2026.101445_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2025.09.003","article-title":"Wiring and rewiring PANoptosis: molecular vulnerabilities for targeting inflammatory cell death in human disease","volume":"86","author":"Upmanyu","year":"2025","journal-title":"Cytokine Growth Factor. Rev."},{"key":"10.1016\/j.drup.2026.101445_bib50","article-title":"WEE-family kinases in cancer: synthetic lethal interactions and drug discovery","author":"Wang","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drup.2026.101445_bib51","article-title":"Discovery of Natural Compound alpha-Hederin via Large-Scale Screening as a Targeted JAK\/STAT3 Inhibitor for Ovarian Cancer Therapy","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.drup.2026.101445_bib52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s44178-025-00152-w","article-title":"Colorectal cancer: highlight the clinical research current progress","volume":"4","author":"Wang","year":"2025","journal-title":"Holist. Integr. Oncol."},{"key":"10.1016\/j.drup.2026.101445_bib53","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/0008-5472.CAN-22-4017","article-title":"SENP1 Decreases RNF168 PHase Separation to Promote Dna Damage Repair and Drug Resistance in Colon Cancer","volume":"83","author":"Wei","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101445_bib54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12943-023-01887-8","article-title":"hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1\/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma","volume":"22","author":"Xu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101445_bib55","article-title":"Biomimetic hybrid PROTAC nanovesicles block multiple DNA repair pathways to overcome temozolomide resistance against orthotopic glioblastoma","volume":"37","author":"Xu","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.drup.2026.101445_bib56","article-title":"EM2, a natural product MST1\/2 kinase activator, suppresses non-small cell lung cancer via hippo pathway activation","volume":"13","author":"Yang","year":"2026","journal-title":"Adv. Sci. (Weinh. )"},{"key":"10.1016\/j.drup.2026.101445_bib57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-024-01762-y","article-title":"Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study","volume":"9","author":"Yang","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.drup.2026.101445_bib58","first-page":"2190","article-title":"Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth","volume":"60","author":"Yokoyama","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101445_bib59","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41401-024-01376-8","article-title":"Baicalin inhibits PANoptosis by blocking mitochondrial Z-DNA formation and ZBP1-PANoptosome assembly in macrophages","volume":"46","author":"You","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.drup.2026.101445_bib60","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12943-024-02130-8","article-title":"Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101445_bib61","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12943-024-02180-y","article-title":"THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K\/AKT activation in colorectal cancer","volume":"23","author":"Zhou","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2026.101445_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101287","article-title":"Targeting DNA damage response pathways in tumor drug resistance: mechanisms, clinical implications, and future directions","volume":"83","author":"Zhu","year":"2025","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.drup.2026.101445_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101206","article-title":"Harnessing phytochemicals: innovative strategies to enhance cancer immunotherapy","volume":"79","author":"Zhu","year":"2025","journal-title":"Drug. Resist. Updat."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:49:31Z","timestamp":1784836171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626000968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":63,"alternative-id":["S1368764626000968"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101445","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting LIG1 to overcome oxaliplatin resistance by inducing PANoptosis in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101445","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101445"}}